tradingkey.logo

Cargo Therapeutics gains on reduced workforce, eyes merger

ReutersMar 19, 2025 9:22 AM

Shares of drug developer Cargo Therapeutics CRGX.O rise 21% to $4.60 premarket

On Tuesday, co said it is reducing its workforce by about 90%

CRGX appointed Anup Radhakrishnan as interim CEO to lead the co through a potential merger or acquisition

As of December 31, 2024, co had about 167 full-time employees - SEC filing

Co also said it is stopping its experimental cancer therapy, CRG-023, and allogeneic platform

Earlier this year, co halted a mid-stage trial for cancer treatment

CRGX has $368.1 million in cash, as of December 31, 2024

CRGX fell 36.5% last year

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI